国家神经系统疾病临床医学研究中心数据管理与共享系统

Data Management And Sharing System of China National Clinical Research Center for Neurological Diseases

《国家中心数据管理与共享系统操作说明书 —— 研究者部分》

Soluble lectin-like oxidized low-density Lipoproteinreceptor-1 and recurrent stroke: A nested case-control study

第一作者：Anxin Wang,Xue Tian,Jie Xu

通讯作者：Xia Meng,Yongjun Wang

nested case–control study prognosis recurrent stroke soluble lectin-like oxidized low-density lipoproteinreceptor-1

基本信息

2022-07-31

已发表文章

发表杂志：CNS Neuroscience & Therapeutics

发表类型: Original Contributions

影响因子(IF): 7.035

PMID: 35909324 Pubmed原文链接 全文下载

主要研究背景及目的

The prognostic value of soluble lectin-like oxidized low-density lipoproteinreceptor-1 (sLOX-1) for stroke was unclearly. This study aimed to investigate the association between sLOX-1 and recurrent stroke in patients with acute ischemic stroke (AIS) or transient ischemic attack (TIA).

方法

Data were obtained from the Third China National Stroke Registry. Eligible cases consisted of 400 patients who developed recurrent stroke within 1-year followup, 800 controls were selected using age- and sex-matched with a 1:2 case–control ratio. Conditional logistic regressions were used to evaluate the association between sLOX-1 and recurrent stroke.

结论

sLOX-1 was positively associated with the risk of recurrent stroke, which may be a candidate biomarker to improve risk stratification of recurrent stroke.

主要结果

Among 1200 patients included in this study, the median (interquartile range) of sLOX-1 was 247.12 (132.81–413.58) ng/L. After adjustment for conventional confounding factors, the odds ratio with 95% confidence interval in the highest tertile versus the lowest tertile was 2.23 (1.61–3.08) for recurrent stroke, 2.31 (1.64–3.24) for ischemic stroke, 2.30 (1.66–3.19) for combined vascular events within 1-year follow-up. Furthermore, the addition of sLOX-1 to a conventional risk model had an incremental effect on predictive value for recurrent stroke (C-statistics 0.76, p< 0.0001; integrated discrimination improvement 13.38%, p< 0.0001; net reclassification improvement 55.39%, p< 0.0001). Similar results were observed when the timepoint was set up as 3 months. Subgroup analysis showed the association between higher sLOX-1 and recurrent stroke was more pronounced in patients with a history of stroke (p for interaction = 0.0062).